FR3050461A1 - - Google Patents
Download PDFInfo
- Publication number
- FR3050461A1 FR3050461A1 FR1753439A FR1753439A FR3050461A1 FR 3050461 A1 FR3050461 A1 FR 3050461A1 FR 1753439 A FR1753439 A FR 1753439A FR 1753439 A FR1753439 A FR 1753439A FR 3050461 A1 FR3050461 A1 FR 3050461A1
- Authority
- FR
- France
- Prior art keywords
- culture vessel
- test
- culture
- microorganism
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000523 sample Substances 0.000 claims abstract description 668
- 238000012360 testing method Methods 0.000 claims abstract description 407
- 244000005700 microbiome Species 0.000 claims abstract description 325
- 230000000813 microbial effect Effects 0.000 claims abstract description 232
- 238000000034 method Methods 0.000 claims abstract description 195
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 131
- 238000001514 detection method Methods 0.000 claims abstract description 83
- 239000004599 antimicrobial Substances 0.000 claims abstract description 74
- 239000002773 nucleotide Substances 0.000 claims abstract description 57
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 57
- 238000011330 nucleic acid test Methods 0.000 claims abstract description 55
- 239000003550 marker Substances 0.000 claims abstract description 54
- 230000002068 genetic effect Effects 0.000 claims abstract description 51
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 32
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims abstract description 30
- 239000002853 nucleic acid probe Substances 0.000 claims abstract description 30
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 29
- 238000009635 antibiotic susceptibility testing Methods 0.000 claims description 167
- 230000012010 growth Effects 0.000 claims description 147
- 238000006243 chemical reaction Methods 0.000 claims description 58
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 56
- 230000003321 amplification Effects 0.000 claims description 55
- 238000010438 heat treatment Methods 0.000 claims description 50
- 238000009640 blood culture Methods 0.000 claims description 47
- 238000009396 hybridization Methods 0.000 claims description 44
- 239000001963 growth medium Substances 0.000 claims description 42
- 238000012258 culturing Methods 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 28
- 239000000178 monomer Substances 0.000 claims description 28
- 238000013019 agitation Methods 0.000 claims description 27
- 238000012544 monitoring process Methods 0.000 claims description 25
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 238000013095 identification testing Methods 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 24
- 238000003384 imaging method Methods 0.000 claims description 23
- 239000002028 Biomass Substances 0.000 claims description 19
- 230000002708 enhancing effect Effects 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 13
- 238000011156 evaluation Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 238000005096 rolling process Methods 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000012512 characterization method Methods 0.000 abstract description 8
- 108020004414 DNA Proteins 0.000 description 118
- 210000004027 cell Anatomy 0.000 description 80
- 230000032258 transport Effects 0.000 description 44
- 241000894006 Bacteria Species 0.000 description 42
- 239000000047 product Substances 0.000 description 33
- 239000003242 anti bacterial agent Substances 0.000 description 27
- 229940088710 antibiotic agent Drugs 0.000 description 24
- 230000003115 biocidal effect Effects 0.000 description 22
- 238000011534 incubation Methods 0.000 description 21
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 19
- 244000052769 pathogen Species 0.000 description 19
- 206010040047 Sepsis Diseases 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 14
- 230000009089 cytolysis Effects 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 230000033001 locomotion Effects 0.000 description 14
- 238000000926 separation method Methods 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 229960003405 ciprofloxacin Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 241000272478 Aquila Species 0.000 description 8
- 241000191940 Staphylococcus Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000000386 microscopy Methods 0.000 description 8
- 238000007826 nucleic acid assay Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000233866 Fungi Species 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 238000009413 insulation Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 229960004261 cefotaxime Drugs 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000007773 growth pattern Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000009629 microbiological culture Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 239000006994 mh medium Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 108020000946 Bacterial DNA Proteins 0.000 description 4
- 108091028732 Concatemer Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960000484 ceftazidime Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 229960002260 meropenem Drugs 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 229960002292 piperacillin Drugs 0.000 description 4
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 4
- 229960003865 tazobactam Drugs 0.000 description 4
- 108020004256 Beta-lactamase Proteins 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000004557 single molecule detection Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010063905 Ampligase Proteins 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000194049 Streptococcus equinus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003914 blood derivative Substances 0.000 description 2
- 238000002815 broth microdilution Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000004794 expanded polystyrene Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004683 skeletal myoblast Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 241000588917 Citrobacter koseri Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241001527609 Cryptococcus Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101800000836 Red carotenoid-binding protein Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000533331 Salmonella bongori Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001147695 Staphylococcus caprae Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- -1 lincosamides Chemical class 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 238000012473 microbial detection method Methods 0.000 description 1
- 230000003158 microbiostatic effect Effects 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000012782 phase change material Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229940115921 streptococcus equinus Drugs 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 101150114434 vanA gene Proteins 0.000 description 1
- 101150037181 vanB gene Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/142—Apparatus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/146—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
- A01N1/148—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/12—Means for regulation, monitoring, measurement or control, e.g. flow regulation of temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Thermal Sciences (AREA)
- Biomedical Technology (AREA)
- Sustainable Development (AREA)
- Mechanical Engineering (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/058952 WO2016170086A1 (en) | 2015-04-24 | 2016-04-21 | Medical sample transportation container |
| GB201606991 | 2016-04-21 | ||
| GB1617353.6A GB2554767A (en) | 2016-04-21 | 2016-10-13 | Detecting and characterising a microorganism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR3050461A1 true FR3050461A1 (enExample) | 2017-10-27 |
Family
ID=57680912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1753439A Ceased FR3050461A1 (enExample) | 2016-04-21 | 2017-04-20 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11845978B2 (enExample) |
| EP (1) | EP3294057B1 (enExample) |
| FR (1) | FR3050461A1 (enExample) |
| GB (1) | GB2554767A (enExample) |
| WO (1) | WO2017182645A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210172000A1 (en) * | 2017-04-19 | 2021-06-10 | CAP Diagnostics, LLC, dba Pathnostics | Methods and systems for preparing therapeutic solutions for polymicrobial infections |
| US11053532B2 (en) | 2017-04-19 | 2021-07-06 | CAP Diagnostics, LLC | Methods for treating polymicrobial infections |
| WO2019108124A1 (en) * | 2017-11-30 | 2019-06-06 | Ascilion Ab | A system for assessing microbial susceptibility to antibiotic agents |
| AU2018353924A1 (en) | 2017-12-29 | 2019-07-18 | Clear Labs, Inc. | Automated priming and library loading device |
| CA3167249A1 (en) * | 2020-02-25 | 2021-09-02 | Mansour Samadpour | Incubator for enrichment during transport |
| EP4294521A4 (en) * | 2021-02-17 | 2025-01-08 | Cap Diagnostics, LLC, DBA Pathnostics | Methods and systems for determining suitability of compositions for inhibiting growth of polymicrobial samples |
| EP4565712A1 (en) * | 2022-09-15 | 2025-06-11 | General Electric Company | Method and apparatus for using lyophilized reagent beads for antimicrobial susceptibility testing |
| CN116218893B (zh) * | 2023-03-24 | 2025-07-29 | 哈尔滨医科大学 | 一种通过体外扩增重组质粒在其编码基因上生成短片段串联重复序列的方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997012029A1 (en) * | 1995-09-29 | 1997-04-03 | Idexx Laboratories, Inc. | Self-contained incubator for growth of microorganism |
| US20050037408A1 (en) * | 2003-07-24 | 2005-02-17 | Christensen Jeffrey E. | Rapid identification of bacteria from positive blood cultures |
| US20100124763A1 (en) * | 2008-10-31 | 2010-05-20 | Biomerieux, Inc. | Method for detection, characterization and/or identification of microorganisms in a sealed container |
| US20140278136A1 (en) * | 2013-03-15 | 2014-09-18 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
| WO2015189390A1 (en) * | 2014-06-13 | 2015-12-17 | Q-Linea Ab | Method for detecting and characterising a microorganism |
| US20160053219A1 (en) * | 2014-08-25 | 2016-02-25 | Opgen, Inc. | Systems, methods, and devices for temperature control |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3159384A (en) | 1962-07-02 | 1964-12-01 | Bio Science Labor | Agitator for laboratory tubes and flasks |
| US3764780A (en) | 1971-06-16 | 1973-10-09 | C Ellis | Blood culture apparatus |
| US3975001A (en) | 1973-10-19 | 1976-08-17 | American Hospital Supply Corporation | Apparatus for mixing fluids held in tubes |
| GB1507026A (en) * | 1974-04-11 | 1978-04-12 | Nat Res Dev | Endoprosthetic devices |
| US4004883A (en) | 1975-07-11 | 1977-01-25 | G. D. Searle & Co. | Sensing, leveling and mixing apparatus |
| DE7922217U1 (de) | 1979-08-03 | 1979-11-22 | Binz Gmbh & Co, 7073 Lorch | Warmhaltebehaelter zum transport von infusionen o.dgl. |
| US4629686A (en) | 1982-02-19 | 1986-12-16 | Endotronics, Inc. | Apparatus for delivering a controlled dosage of a chemical substance |
| FI843529A0 (fi) | 1983-01-10 | 1984-09-10 | Gen Probe Inc | Foerfarande foer detektering, identifiering och kvantitering av organismer och virus. |
| EP0122581B1 (en) | 1983-04-15 | 1991-01-16 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Process for isolating bacteria in blood |
| US4666850A (en) | 1983-10-28 | 1987-05-19 | Becton, Dickinson And Company | Microbial pathogen detecting system and process |
| US4652517A (en) | 1984-06-11 | 1987-03-24 | Diagnostic Research Limited Partnership | Methods for the in vitro detection and identification of unknown pathogens or genetic entities |
| AU1363688A (en) | 1987-02-12 | 1988-09-14 | Sdi Diagnostics, Inc. | Test system, test device and method for detecting pathogenic organisms and antibiotic resistance genes in body fluids |
| US5217876A (en) | 1988-03-15 | 1993-06-08 | Akzo N.V. | Method for detecting microorganisms |
| CA2016699C (en) | 1989-05-15 | 2003-11-18 | Paul N. Marshall | Lytic agents and uses thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6406844B1 (en) | 1989-06-07 | 2002-06-18 | Affymetrix, Inc. | Very large scale immobilized polymer synthesis |
| US6346413B1 (en) | 1989-06-07 | 2002-02-12 | Affymetrix, Inc. | Polymer arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5183994A (en) | 1990-10-26 | 1993-02-02 | Bowles Sr Dale D | Heated drug box |
| US5052812A (en) | 1990-11-19 | 1991-10-01 | New Brunswick Scientific Co., Inc. | Bath shaker |
| US5316146A (en) | 1991-03-06 | 1994-05-31 | Ulster Scientific, Inc. | Vial transporter |
| EP0626067A4 (en) | 1992-02-07 | 1997-06-25 | Abbott Lab | METHOD FOR ACCURATELY COUNTING AND SENSITIVELY CLASSIFYING HETEROGENEOUS CELL POPULATIONS UNDER CYTOLYTIC PROCESSING CONDITIONS. |
| US5882918A (en) | 1995-08-08 | 1999-03-16 | Genespan Corporation | Cell culture incubator |
| SE9400522D0 (sv) | 1994-02-16 | 1994-02-16 | Ulf Landegren | Method and reagent for detecting specific nucleotide sequences |
| EP0695941B1 (en) | 1994-06-08 | 2002-07-31 | Affymetrix, Inc. | Method and apparatus for packaging a chip |
| US20020055101A1 (en) | 1995-09-11 | 2002-05-09 | Michel G. Bergeron | Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| AU4586096A (en) | 1995-03-10 | 1996-09-19 | Becton Dickinson & Company | Sample processing method for whole blood |
| JPH08285839A (ja) | 1995-04-13 | 1996-11-01 | Daiichi Kigyo:Kk | 病理検体等運搬用容器 |
| US5577837A (en) | 1995-05-19 | 1996-11-26 | Forma Scientific, Inc. | Temperature controlled HEPA-filtered console shaker |
| US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
| SE506908C2 (sv) | 1995-09-08 | 1998-03-02 | Ulf Landegren Inst F Medicinsk | Medicinsk användning av padlockprober |
| US5994066A (en) | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| JP3974941B2 (ja) | 1995-11-21 | 2007-09-12 | イェール ユニバーシティ | 単分子セグメントの増幅および検出 |
| JP2001504210A (ja) | 1995-12-08 | 2001-03-27 | ライテル，マルチン | アレルギー性障害のインビトロ診断のための方法および装置 |
| SE9601676D0 (sv) | 1996-04-30 | 1996-04-30 | Ulf Landegren | Improved probing of specific mucleic acids |
| US5770394A (en) | 1996-05-22 | 1998-06-23 | Becton Dickinson And Company | Method and apparatus for detecting bacteria using a blood culture froth |
| EP0822261B1 (en) | 1996-07-29 | 2002-07-03 | Academia Sinica | Methods for rapid antimicrobial susceptibility testing |
| US5817508A (en) | 1996-09-27 | 1998-10-06 | Becton Dickinson And Company | Blood culture apparatus having an auto-unloading and sorting device |
| EP0990142A4 (en) | 1996-12-31 | 2000-09-27 | Genometrix Genomics Inc | MULTIPLEXED MOLECULAR ANALYSIS METHOD AND DEVICE |
| US6255467B1 (en) | 1997-11-06 | 2001-07-03 | Pathobiotek Diagnostics Inc. | Human blood bacterium |
| US6028293A (en) | 1998-04-20 | 2000-02-22 | Tcp Reliable Inc. | Temperature-controlled container with heating means |
| US6059446A (en) | 1998-05-08 | 2000-05-09 | Dschida; William J. A. | Apparatus for mixing the contents of microcentrifuge tubes |
| AU1543000A (en) | 1998-12-11 | 2000-07-03 | Visible Genetics Inc. | Method and kit for the characterization of antibiotic-resistance mutations in (mycobacterium) tuberculosis |
| EP1177448A2 (en) | 1999-04-29 | 2002-02-06 | Dade MicroScan Inc. | A combined rapid anti-microbial susceptibility assay and microorganism identification system |
| ES2367979T3 (es) | 1999-05-25 | 2011-11-11 | Millipore Corporation | Procedimiento para detectar y enumerar microorganismos rápidamente en preparaciones de células de mamíferos usando la bioluminiscencia del atp. |
| ATE333938T1 (de) | 1999-05-28 | 2006-08-15 | Cepheid | Patrone zum durchführen einer chemischen reaktion |
| JP2001103981A (ja) | 1999-08-03 | 2001-04-17 | Nisshinbo Ind Inc | 結核菌診断キット |
| US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| JP2001169778A (ja) | 1999-12-17 | 2001-06-26 | Joji Oshima | 迅速細菌遺伝子検査法及びキット |
| CN2436459Y (zh) | 2000-08-14 | 2001-06-27 | 青岛市家用电器研究所 | 一种血液运输用储藏箱 |
| US20040121313A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in organs for transplantation |
| US7223363B2 (en) | 2001-03-09 | 2007-05-29 | Biomicro Systems, Inc. | Method and system for microfluidic interfacing to arrays |
| US7008788B2 (en) | 2001-07-30 | 2006-03-07 | Agilent Technologies, Inc. | Containers for supports comprising biopolymers |
| US6803208B2 (en) | 2001-07-30 | 2004-10-12 | The United States Of America As Represented By The Secretary Of The Navy | Automated epifluorescence microscopy for detection of bacterial contamination in platelets |
| GB2378245A (en) | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
| CA2458802C (en) | 2001-09-06 | 2016-06-07 | Genomic Profiling Systems, Inc. | Rapid and sensitive detection of molecules |
| US20030098271A1 (en) | 2001-11-26 | 2003-05-29 | Ralph Somack | Capsule and tray systems for combined sample collection, archiving, purification, and PCR |
| DE10201463B4 (de) | 2002-01-16 | 2005-07-21 | Clondiag Chip Technologies Gmbh | Reaktionsgefäß zur Durchführung von Array-Verfahren |
| RU2228735C2 (ru) | 2002-04-10 | 2004-05-20 | Абанин Вячеслав Владимирович | Устройство для хранения концентрата тромбоцитов |
| DE10222133A1 (de) | 2002-05-17 | 2003-12-04 | Gl Biotech Gmbh | Verfahren zur Nukleinsäure-Extraktion und Nukleinsäure-Reinigung |
| WO2003097831A1 (en) | 2002-05-17 | 2003-11-27 | Gl Bio Tech Gmbh | Method for nucleic acid extraction and nucleic acid purification |
| JP2006516193A (ja) | 2002-12-06 | 2006-06-29 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヒトおよび動物における病原体の迅速な同定方法 |
| US20060094034A1 (en) | 2003-04-30 | 2006-05-04 | Roland Brousseau | Virulence and antibiotic resistance array and uses thereof |
| AU2004265570B2 (en) | 2003-05-13 | 2009-01-08 | Gen-Probe Incorporated | Method and kit for identifying antibiotic-resistant microorganisms |
| WO2005027714A2 (en) | 2003-07-12 | 2005-03-31 | Accelr8 Technology Corporation | Sensitive and rapid biodetection |
| US7341841B2 (en) | 2003-07-12 | 2008-03-11 | Accelr8 Technology Corporation | Rapid microbial detection and antimicrobial susceptibility testing |
| US20120077206A1 (en) | 2003-07-12 | 2012-03-29 | Accelr8 Technology Corporation | Rapid Microbial Detection and Antimicrobial Susceptibility Testing |
| US20050042144A1 (en) | 2003-08-18 | 2005-02-24 | A. Robert Hubbard | Portable insulated container for biological specimens |
| CN102970829B (zh) | 2003-09-12 | 2016-01-20 | 独立行政法人产业技术综合研究所 | 衬底的制备方法 |
| WO2005068647A2 (en) | 2003-12-09 | 2005-07-28 | Biomerieux, Inc. | Methods for detecting bacterial pathogens |
| US7387883B2 (en) | 2003-12-09 | 2008-06-17 | Biomerieux, Inc | Methods for detecting bacterial pathogens |
| EP1574583A1 (en) | 2004-03-10 | 2005-09-14 | Roche Diagnostics GmbH | Methods for isolation of bacteria from biological samples |
| US7547526B2 (en) | 2004-03-15 | 2009-06-16 | Purdue Research Foundation | Cell concentration and pathogen recovery |
| US7580920B2 (en) | 2004-07-22 | 2009-08-25 | Microsoft Corporation | System and method for graceful degradation of a database query |
| US7662562B2 (en) | 2004-08-10 | 2010-02-16 | Becton, Dickinson And Company | Method for rapid identification of microorganisms |
| DE102005009479A1 (de) | 2005-03-02 | 2006-09-07 | Molzym Gmbh & Co. Kg | Verwendung von Nukleasen zum Abbau von Nukleinsäure in Gegenwart von chaotropen Agenzien und/oder Tensiden |
| US20060223098A1 (en) | 2005-03-31 | 2006-10-05 | Lane David J | Circularizable nucleic acid probes and amplification methods |
| WO2007033051A2 (en) | 2005-09-12 | 2007-03-22 | Genzyme Corporation | Thermally insulated transport container for cell-based products and related methods |
| US20080286757A1 (en) | 2005-09-15 | 2008-11-20 | Microphage Incorporated | Method and Apparatus for Identification of Microorganisms Using Bacteriophage |
| WO2007058898A2 (en) | 2005-11-10 | 2007-05-24 | Panomics, Inc. | Detection of nucleic acids through amplification of surrogate nucleic acids |
| US20090209031A1 (en) | 2006-01-26 | 2009-08-20 | Tyco Healthcare Group Lp | Medical device package |
| US7334516B2 (en) | 2006-03-08 | 2008-02-26 | Taiwan Supercritical Technology Co., Ltd. | Aging device for liquor or wine |
| AU2007258455B2 (en) | 2006-06-06 | 2013-05-02 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| US7819934B2 (en) | 2006-07-14 | 2010-10-26 | Xcellerex, Inc. | Environmental containment systems |
| JP4872511B2 (ja) | 2006-08-02 | 2012-02-08 | 株式会社日立製作所 | 温度調整部材 |
| WO2008017097A1 (en) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | Method for isolating cells |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US20080145919A1 (en) | 2006-12-18 | 2008-06-19 | Franklin Thomas D | Portable organ and tissue preservation apparatus, kit and methods |
| CA2684311A1 (en) | 2007-04-18 | 2008-10-30 | Cornell University | Microorganism detection method and apparatus |
| CN101130808B (zh) | 2007-07-27 | 2011-08-17 | 南京市胸科医院 | 分枝杆菌快速培养药敏及鉴定微量检测法及装置 |
| EP2185681B1 (en) | 2007-08-02 | 2014-12-17 | Université Laval | Concentration and enrichment of microbial cells and microbial nucleic acids from bodily fluids |
| DE102007041864B4 (de) * | 2007-09-04 | 2012-05-03 | Sirs-Lab Gmbh | Verfahren zum Nachweis von Bakterien und Pilzen |
| EP2056114A1 (en) | 2007-10-29 | 2009-05-06 | Koninklijke Philips Electronics N.V. | Automatic detection of infectious diseases |
| EP2087934A1 (de) | 2008-02-07 | 2009-08-12 | Qiagen GmbH | Verfahren und Vorrichtung zur automatisierten Prozessierung einer Probe |
| DE102008029356A1 (de) | 2008-06-20 | 2009-12-24 | Siemens Healthcare Diagnostics Gmbh | Verfahren zur Aufreinigung von Nukleinsäuren, insbesondere aus fixiertem Gewebe |
| US8512975B2 (en) | 2008-07-24 | 2013-08-20 | Biomerieux, Inc. | Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements |
| US20110269130A1 (en) | 2008-10-24 | 2011-11-03 | Song Shi | Antibiotice Susceptibility Profiling Methods |
| KR20110091719A (ko) | 2008-10-31 | 2011-08-12 | 바이오메리욱스, 인코포레이티드. | 식별제를 사용한 미생물의 분리 및 특성규명 방법 |
| CA2740836C (en) | 2008-10-31 | 2017-03-21 | Biomerieux, Inc. | Methods for separation, characterization and/or identification of microorganisms using spectroscopy |
| DK200801722A (en) | 2008-12-05 | 2010-06-06 | Unisensor As | Optical sectioning of a sample and detection of particles in a sample |
| CN102803959B (zh) | 2009-05-15 | 2015-07-08 | 生物梅里埃有限公司 | 用于样品中的微生物剂的快速的识别和/或表征的系统和方法 |
| AU2010248902B2 (en) | 2009-05-15 | 2015-02-26 | Biomerieux, Inc. | Automated microbial detection apparatus |
| WO2011019874A1 (en) | 2009-08-12 | 2011-02-17 | President And Fellows Of Harvard College | Biodetection methods and compositions |
| EP2325312A1 (de) | 2009-11-19 | 2011-05-25 | Qiagen GmbH | Verfahren zur selektiven Anreicherung und Isolierung mikrobieller und optional zusätzlich viraler Nukleinsäuren |
| EP2333105A1 (en) | 2009-12-08 | 2011-06-15 | Koninklijke Philips Electronics N.V. | Selective lysis of cells |
| MX345230B (es) | 2010-02-24 | 2017-01-20 | The Broad Inst Inc * | Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos. |
| DE102010012790B4 (de) | 2010-03-25 | 2015-08-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Inkubatoreinrichtung und Verfahren zu deren Betrieb |
| CN101845390B (zh) | 2010-04-30 | 2013-09-11 | 武汉迪艾斯科技有限公司 | 自动化细菌培养仪 |
| EP2388312A1 (en) | 2010-05-17 | 2011-11-23 | Curetis AG | Universally applicable lysis buffer and processing methods for the lysis of bodily samples |
| US20130261196A1 (en) | 2010-06-11 | 2013-10-03 | Lisa Diamond | Nucleic Acids For Multiplex Organism Detection and Methods Of Use And Making The Same |
| JP5863791B2 (ja) | 2010-07-20 | 2016-02-17 | ビオメリュー・インコーポレイテッド | 比色センサを有する血液培養ボトル用検出装置 |
| CN104306005A (zh) * | 2010-11-04 | 2015-01-28 | 日立化成株式会社 | 用于体外刺激全血的便携设备 |
| EP2710127A4 (en) | 2011-05-20 | 2014-12-03 | Advandx Inc | SELECTIVE ULTRASONIC LYSE OF BLOOD AND OTHER BIOLOGICAL FLUIDS AND WOVEN |
| CN103518132B (zh) | 2011-06-06 | 2015-11-25 | 拜奥卡蒂斯股份有限公司 | 通过离子型表面活性剂选择性裂解细胞 |
| WO2013016211A1 (en) | 2011-07-22 | 2013-01-31 | Biomerieux, Inc. | Method and kit isolating microorganisms from culture |
| US8603769B2 (en) | 2011-10-07 | 2013-12-10 | Becton, Dickinson And Company | Method for direct and rapid identification of microorganisms and antimicrobial susceptibility testing from positive blood cultures |
| WO2013101743A2 (en) | 2011-12-30 | 2013-07-04 | Abbott Molecular, Inc. | Microorganism nucelic acid purification from host samples |
| US10475527B2 (en) | 2012-03-22 | 2019-11-12 | Biomerieux, Inc. | Method and system for detection of microbial growth in a specimen container |
| WO2013163210A1 (en) | 2012-04-23 | 2013-10-31 | Philip Alexander Rolfe | Method and system for detection of an organism |
| JP6018808B2 (ja) | 2012-06-12 | 2016-11-02 | 株式会社日立ハイテクノロジーズ | 微生物検査方法および検査システム |
| EP2684947A1 (en) | 2012-07-09 | 2014-01-15 | Biocartis SA | A method for filtering a biological sample |
| CA2923795A1 (en) | 2012-09-10 | 2014-03-13 | Accelerate Diagnostics, Inc. | Same-day blood culture with digital microscopy |
| US10174366B2 (en) | 2012-11-14 | 2019-01-08 | Olink Bioscience Ab | Localised RCA-based amplification method |
| US20140287408A1 (en) | 2013-03-13 | 2014-09-25 | Abbott Molecular Inc. | Target sequence enrichment |
| GB201321123D0 (en) | 2013-11-29 | 2014-01-15 | Linea Ab Q | Amplification of circular molecules |
| GB2520765A (en) | 2013-12-02 | 2015-06-03 | Vanadis Diagnostics Ab | Multiplex detection of nucleic acids |
| EP2942394A1 (en) | 2014-05-09 | 2015-11-11 | Molzym GmbH & Co. KG | New method for isolating microbial DNA |
| CN204255722U (zh) | 2014-12-15 | 2015-04-08 | 王东生 | 血液孵育器 |
| AU2016212166B2 (en) | 2015-01-26 | 2019-10-17 | Ventana Medical Systems, Inc. | Transporter systems, assemblies and associated methods for transporting tissue samples |
| EP3283640B1 (en) * | 2015-04-17 | 2021-03-03 | Vax-Immune LLC | Portable disposable re-usable culture device for rapid diagnosis of infectious agents |
| GB201507026D0 (en) * | 2015-04-24 | 2015-06-10 | Linea Ab Q | Medical sample transportation container |
| GB201511129D0 (en) * | 2015-06-24 | 2015-08-05 | Linea Ab Q | Method of determining antimicrobial susceptibility of a microorganism |
| US10407659B2 (en) * | 2015-11-09 | 2019-09-10 | Sahar M. H Jaffal | Mini-incubator carrier box “Mini-incubator” |
-
2016
- 2016-10-13 GB GB1617353.6A patent/GB2554767A/en not_active Withdrawn
-
2017
- 2017-04-20 FR FR1753439A patent/FR3050461A1/fr not_active Ceased
- 2017-04-21 US US16/094,699 patent/US11845978B2/en active Active
- 2017-04-21 EP EP17719557.5A patent/EP3294057B1/en active Active
- 2017-04-21 WO PCT/EP2017/059542 patent/WO2017182645A1/en not_active Ceased
-
2023
- 2023-10-30 US US18/385,099 patent/US20240368670A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997012029A1 (en) * | 1995-09-29 | 1997-04-03 | Idexx Laboratories, Inc. | Self-contained incubator for growth of microorganism |
| US20050037408A1 (en) * | 2003-07-24 | 2005-02-17 | Christensen Jeffrey E. | Rapid identification of bacteria from positive blood cultures |
| US20100124763A1 (en) * | 2008-10-31 | 2010-05-20 | Biomerieux, Inc. | Method for detection, characterization and/or identification of microorganisms in a sealed container |
| US20140278136A1 (en) * | 2013-03-15 | 2014-09-18 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
| WO2015189390A1 (en) * | 2014-06-13 | 2015-12-17 | Q-Linea Ab | Method for detecting and characterising a microorganism |
| US20160053219A1 (en) * | 2014-08-25 | 2016-02-25 | Opgen, Inc. | Systems, methods, and devices for temperature control |
| WO2016033077A1 (en) * | 2014-08-25 | 2016-03-03 | Opgen, Inc. | Systems, methods, and devices for temperature control |
Non-Patent Citations (2)
| Title |
|---|
| MARK BROOKES ET AL: "Pathology TRANSPORT OF PATHOLOGY SAMPLES GP/MP6 Version 3.4 / August 2014 Page 1 of 11 CONTROLLED COPIES MUST BE SIGNED AND PHOTOCOPIES ARE NOT ALLOWED POLICY FOR THE TRANSPORT OF PATHOLOGY SAMPLES Reviewed by Approved by Summary of Changes <Signature> <Signature> Added ISO15189 requirements for tem", 22 August 2014 (2014-08-22), XP055555057, Retrieved from the Internet <URL:http://www.southend.nhs.uk/media/64058/gp-mp6.pdf> [retrieved on 20190212] * |
| WALTER C OLSON ET AL: "R Background", JOURNAL OF TRANSLATIONAL MEDICINE, 1 January 2011 (2011-01-01), pages 26, XP055554919, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063218/pdf/1479-5876-9-26.pdf> * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2554767A (en) | 2018-04-11 |
| US20240368670A1 (en) | 2024-11-07 |
| US11845978B2 (en) | 2023-12-19 |
| GB201617353D0 (en) | 2016-11-30 |
| EP3294057A1 (en) | 2018-03-21 |
| WO2017182645A1 (en) | 2017-10-26 |
| EP3294057B1 (en) | 2018-12-12 |
| US20190119724A1 (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3050461A1 (enExample) | ||
| US11505835B2 (en) | Method for determining the identity and antimicrobial susceptibility of a microorganism | |
| US10457934B2 (en) | Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection | |
| IL287247B2 (en) | High-resolution systems, kits, devices and methods for high-throughput microbiology applications | |
| EP2252892B1 (fr) | Procede de detection en temps reel de microorganismes dans un milieu de culture liquide par agglutination | |
| Endimiani et al. | The evolving role of the clinical microbiology laboratory in identifying resistance in Gram-negative bacteria: an update | |
| Khardori | Future of diagnostic microbiology | |
| WO2020252084A1 (en) | Methods and compositions for high sensitivity detection of biothreat pathogens | |
| WO2013104864A1 (fr) | Procede de detection et d'identification directe par voie optique d'un microorganisme dans un echantillon biologique | |
| CN103476945A (zh) | 使用基于分子核酸的技术确定细胞活性的改进方法 | |
| CN111849780B (zh) | 一种耐药微生物的筛选方法 | |
| EP2255197B1 (fr) | Procede de detection et/ou de quantification et/ou d'identification in vitro de bacteries dans un materiau biologique | |
| US20250305029A1 (en) | Generation of phased read-sets for genome assembly and haplotype phasing | |
| EP3818181A1 (fr) | Procede et dispositif pour la detection et differenciation de mutations ponctuelles chez des microorganismes par oligochromatographie | |
| JPH10211000A (ja) | 細菌検出方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| RX | Complete rejection |
Effective date: 20200326 |